Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.65 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.65 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.65 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23942909 | 1.00 | TLR8 (0.65) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL21776654 | 1.00 | TLR8 (0.65) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL21795319 | 1.00 | TLR8 (0.65) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL23943040 | 1.00 | TLR8 (0.65) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL23943083 | 0.91 | TLR8 (0.79) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL21795303 | 0.91 | TLR8 (0.79) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL30382225 | 0.91 | TLR8 (0.79) | TLR8TLR9TLR7SSTR4SSTR1 | |
| SCHEMBL21776672 | 0.89 | TLR8 (0.82) | TLR8TLR9TLR7SSTR4ACKR3 | |
| SCHEMBL21795386 | 0.89 | TLR8 (0.82) | TLR8TLR9TLR7SSTR4ACKR3 | |
| SCHEMBL21776668 | 0.89 | TLR8 (0.82) | TLR8TLR9TLR7SSTR4ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3844159-B1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | claimed |
| CN-112638901-A | Novel pyrrolidinylamide compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-09 | — | — | CN | claimed |
| EP-3844159-B1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-20210323977-A1 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-112638901-A | Novel pyrrolidinylamide compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020043271-A1 | NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323977-A1 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, SSB, ARG2 | TLR8 1386/4885TLR9 583/4885TLR7 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.